Scientific overview · Why Complete Elixir uses NMN

Topical NMN: the same molecule, two different products

Two serums can name the same ingredient and differ completely. With NMN, the difference is the formula: how it is designed, stabilised and made.

By Clara Song, Ph.D. · About a 5-minute read · Last reviewed 18 November 2026

English · Français · 한국어 · PDF version

The Complete Elixir formulation bench: glass beakers on magnetic stirrers beside filled amber serum bottles

Quick answer

Published research shows that nicotinamide mononucleotide (NMN) can raise NAD⁺ in human skin cells and influence pathways tied to mitochondrial function, cellular senescence and skin repair. NMN is also highly hydrophilic, formulation-sensitive and difficult to deliver through skin. The value of topical NMN therefore does not come from adding the ingredient. It comes from how the finished formula is designed, stabilised and delivered.

The point most NMN marketing skips

Why does the same molecule make two different products?

Because an ingredient list is a record of the batch, not of the skin. An INCI listing records that NMN was added at manufacture. It does not record how much survives to the point of use, or whether any of it reaches living skin.

Both of those are formulation outcomes, and no label distinguishes them. Two products naming the same molecule can sit at opposite ends of that path.

From the label to the skin: four stages, only the first is recorded on a label Four stages in sequence. Stage 1, added at manufacture, is what an ingredient list records. Stages 2 to 4, remains available at application, crosses the stratum corneum, and reaches viable epidermis, are formulation outcomes that no label records. Each of these is a formulation target, not demonstrated delivery. No quantities are shown. What a label records What no label records: formulation outcomes 01 Added at manufacture In the batching room 02 Remains available at application In the bottle, at the point of use 03 Crosses the stratum corneum At the skin's outer barrier 04 Reaches viable epidermis In living skin Recorded on the label; not demonstrated delivery Formulation target, not demonstrated delivery Formulation target, not demonstrated delivery Formulation target, not demonstrated delivery No quantities are shown. This is a map of the questions a formula has to answer, not a measurement. From the label to the skin: four stages, only the first is recorded on a label Four stages from top to bottom. Stage 1, added at manufacture, is what an ingredient list records. Stages 2 to 4, remains available at application, crosses the stratum corneum, and reaches viable epidermis, are formulation outcomes that no label records. Each is a formulation target, not demonstrated delivery. No quantities are shown. What a label records 01 Added at manufacture In the batching room On the label; not demonstrated delivery What no label records: formulation outcomes 02 Remains available at application In the bottle, at the point of use Formulation target, not demonstrated delivery 03 Crosses the stratum corneum At the skin's outer barrier Formulation target, not demonstrated delivery 04 Reaches viable epidermis In living skin Formulation target, not demonstrated delivery No quantities are shown. A map of the questions a formula has to answer, not a measurement.
Mechanism conceptThe path from the batching room to living skin. An ingredient list records stage 1 only. Stages 2 to 4 are what a formula is designed towards; each is a formulation target, not demonstrated delivery, and no percentage is claimed for any of them. Not evidence that a product works.
The ingredient

What does the research support?

Two findings, both from laboratory models. In human skin cells NMN behaves differently from other NAD⁺ precursors, and in a skin-permeation model it reached the region where it would matter. Neither is a trial of a finished product on human skin.

01

NMN behaves differently in skin from other NAD⁺ precursors

In human skin fibroblasts, NMN produced a distinct gene-expression profile from nicotinamide riboside and nicotinamide, raised NAD⁺, activated sirtuin and autophagy pathways and suppressed senescence.1

Evidence kind: in vitro, human skin fibroblasts

02

In a membrane model, NMN reached the compartment where it would matter

In a skin-permeation model NMN crossed the membrane into the papillary dermis region, and NMN-treated fibroblasts increased Type I collagen production.2

Evidence kind: skin-permeation model plus cell culture

What is not yet supported is stated in full in the evidence brief: its literature search located no published randomised controlled trial of topical NMN on human facial skin.

The formula

What does a formula have to solve?

Three things at once. Three independent research groups describe NMN's topical liability in near-identical terms: high hydrophilicity, poor skin permeability, limited stability.3,4,5

Hydrophilic

NMN is highly water-soluble, and it degrades in solution.

Poorly permeating

Free NMN does not penetrate well, which is why researchers build carriers for it.

Unstable

Stability belongs to the matrix, not to the molecule. Change what NMN is carried in and the result changes with it.

That is why the literature is full of liposomes, nanogels and coated vesicles built to carry it.

Our position

How does Complete Elixir make it?

In our own lab in South Surrey, BC, with no contract manufacturing. That makes every variable below a decision we make and can account for. There are six.

Concentration
1% across all five Youth Saver serums. Above that we could not hold it stably in these bases, so we did not chase a larger number.
Formula environment
Built per SKU, not reused. GREEN and OASIS aqueous; SHIELD, ECLIPSE and TWILIGHT oil-in-water, SHIELD at a high oil fraction. pH controlled to each base.
Stability strategy
NMN encapsulated in a lamellar structure, with antioxidant protection, chelation and pH control applied together.
Manufacturing process
NMN enters at phase 5, 43 °C ceiling, added late and cool rather than carried through the hot phase.
Packaging and storage
Dropper bottles; light-protective glass for SHIELD, ECLIPSE and TWILIGHT, standard for the two aqueous serums. A dropper is not airless, which is why we test repeated opening and why the serums are 30 mL: use within six months of opening, and most clients finish in three to four.
Finished-formula evaluation
45 °C for three months in-house, no phase separation, plus repeated-opening observation on every batch. Four serums show no change; SHIELD deepens in colour at about three months, which we attribute to its magnesium ascorbyl phosphate rather than the NMN. This is physical stability; NMN content was not assayed.
The compounding line: NMN is added in phase 5 under a 43 °C process ceiling A schematic of a five-phase batch with temperature on the vertical axis and no scale. The batch temperature rises through a hot phase in the earlier phases, then falls. NMN is added in phase 5, the last phase, below a dashed line marking the 43 °C process ceiling. Only the phase 5 ceiling is a stated value; the shape of the curve before phase 5 is illustrative. The ceiling is a process limit, not a measurement of how much NMN is preserved. Temperature (no scale) 43 °C process ceiling applies at phase 5 hot phase of the batch NMN added in phase 5, late and cool Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Only the phase 5 ceiling is a stated value. The dashed curve before phase 5 is illustrative, not a recorded temperature. The compounding line: NMN is added in phase 5 under a 43 °C process ceiling A schematic of a five-phase batch with temperature on the vertical axis and no scale. The batch temperature rises through a hot phase in the earlier phases, then falls. NMN is added in phase 5, the last phase, below a dashed line marking the 43 °C process ceiling. Only the phase 5 ceiling is a stated value; the curve before phase 5 is illustrative. The ceiling is a process limit, not a measurement of how much NMN is preserved. Temperature (no scale) 43 °C process ceiling hot phase NMN added in phase 5, late and cool 1 2 3 4 5 Phase Only the phase 5 ceiling is a stated value. The dashed curve before phase 5 is illustrative, not a recorded temperature.
Illustrative schematicThe compounding line, phases 1 to 5. NMN is added in phase 5 under a 43 °C process ceiling, late and cool, instead of being carried through the hot phase of the batch. This is a process ceiling, not measured NMN preservation. Not evidence that a product works.
In practice

What happened when the finished formulas were used?

Three clients were documented on standardised clinical imaging over two to six months. These are observational outcomes of complete protocols, not controlled trials, and each is reported with what it does not show.

The three case studies cover mature, sun-exposed skin over three months, blemish-prone skin with a compromised barrier over two months, and marks and uneven tone over six months. None of them shows that NMN, or any single ingredient, caused the change. Individual results vary.

Sources

Where are the full references?

In the topical NMN evidence brief: all twelve references with DOI links, the counter-evidence, and the limits stated plainly. The five papers cited on this page are listed here. Literature from PubMed.

  1. Kang S, Park J, Cho E, Kim D, Ye S, Jeong ET, Jun SH, Kang NG. Distinctive Gene Expression Profiles and Biological Responses of Skin Fibroblasts to Nicotinamide Mononucleotide: Implications for Longevity Effects on Skin. Biomedicines. 2025;13(10):2395. https://doi.org/10.3390/biomedicines13102395
  2. Betsuno R, Yamane T, Tsuji H, Nakajima Y, Imai M, Bamba T, Uchiyama S. Permeation of Nicotinamide Mononucleotide (NMN) in an Artificial Membrane as a Cosmetic Skin Permeability Test Model. J Cosmet Dermatol. 2025;24(5):e70222. https://doi.org/10.1111/jocd.70222
  3. Sun Z, Li J, Zheng Y, et al. Small extracellular vesicles derived from mesenchymal stromal cells loaded with β-nicotinamide mononucleotide activate NAD/SIRT3 signaling pathway-mediated mitochondrial autophagy to delay skin aging. Stem Cell Res Ther. 2025;16(1):339. https://doi.org/10.1186/s13287-025-04460-w
  4. Ye H, Zhen Y, Chen S, et al. Elastic cationic liposomal nanogels: a novel platform for topical nicotinamide mononucleotide delivery. J Liposome Res. 2025;36(1):13–24. https://doi.org/10.1080/08982104.2025.2584982
  5. Sabbagh F. pH-Responsive Transdermal Release from Poly(vinyl alcohol)-Coated Liposomes and Transethosomes: Investigating the Role of Coating in Delayed Drug Delivery. ACS Appl Bio Mater. 2025;8(5):4093–4103. https://doi.org/10.1021/acsabm.5c00257
Clara Song, Ph.D., founder and formulator of Complete Elixir, in a lab coat

Written and reviewed by Clara Song, Ph.D.

Founder and in-house formulator, COMPLETE ELIXIR · Ph.D. in Data Science · Medical Aesthetician Diploma

Last reviewed: 18 November 2026

This page makes no medical claim and describes no product as a treatment for any condition. It is educational and does not replace medical diagnosis or treatment. Case documentation describes individual observational outcomes from one practice; results are not attributable to any single product or ingredient and individual results vary.

When skin gets complicated, formulation matters.